Monthly Archives: April 2018

http://www.lslog.com/feng-zhang-quietly-starting-new-crispr-based-company-report/Feng Zhang quietly starting new CRISPR-based company: report

Feng Zhang quietly starting new CRISPR-based company: report

Feng Zhang quietly starting new CRISPR-based company: report Beam Therapeutics, a new Cambridge, Massachusetts-based startup co-founded by gene editing innovator Feng Zhang, has raised nearly $100 million in series A […]

http://www.lslog.com/biogen-ceos-pay-jumps-as-he-takes-the-top-seat-but-the-stocks-still-falling/Biogen CEO’s pay jumps as he takes the top seat, but the stock's still falling

Biogen CEO’s pay jumps as he takes the top seat, but the stock's still falling

Biogen CEO’s pay jumps as he takes the top seat, but the stock’s still falling Biogen CEO Michel Vounatsos totted up a healthy $13.6 million in the usual mix of […]

http://www.lslog.com/gsks-shingrix-blows-past-sales-projections-pushing-2018-estimates-to-600m/GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M

GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M

GSK’s Shingrix blows past sales projections, pushing 2018 estimates to 0M GlaxoSmithKline’s Shingrix carried high expectations, but it turns out that those ambitious projections weren’t high enough. In the first quarter, the shingles […]

http://www.lslog.com/jazz-grabs-sparks-priority-review-voucher-for-110m/Jazz grabs Spark’s priority review voucher for $110M

Jazz grabs Spark’s priority review voucher for $110M

Jazz grabs Spark’s priority review voucher for 0M Spark Therapeutics agreed to sell its priority review voucher, good for four months off an FDA decision date for any product, to […]

http://www.lslog.com/after-months-of-mounting-pressure-amid-lurid-allegations-orbimeds-isaly-steps-down/After months of mounting pressure amid lurid allegations, OrbiMed’s Isaly steps down

After months of mounting pressure amid lurid allegations, OrbiMed’s Isaly steps down

After months of mounting pressure amid lurid allegations, OrbiMed’s Isaly steps down Sam Isaly has now finally left OrbiMed, the venture capital firm he founded, amid allegations of sexual impropriety. […]

http://www.lslog.com/kiniksa-and-scholar-rock-gun-for-175m-ipos-as-two-other-biotechs-struggle/Kiniksa and Scholar Rock gun for $175M IPOs as two other biotechs struggle

Kiniksa and Scholar Rock gun for $175M IPOs as two other biotechs struggle

Kiniksa and Scholar Rock gun for 5M IPOs as two other biotechs struggle It was something of an up-and-down week for IPOs: Two biotechs, Alzheimer’s-focused Alzheon and brittle bone drug […]

http://www.lslog.com/proniras-launches-with-barda-funding-to-pit-migraine-drug-against-nerve-agents/Proniras launches with BARDA funding to pit migraine drug against nerve agents

Proniras launches with BARDA funding to pit migraine drug against nerve agents

Proniras launches with BARDA funding to pit migraine drug against nerve agents Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine treatment into a therapy for […]

http://www.lslog.com/milkshake-study-reveals-how-gene-variants-affect-cholesterol/Milkshake study reveals how gene variants affect cholesterol

Milkshake study reveals how gene variants affect cholesterol

Milkshake study reveals how gene variants affect cholesterol In a bid to better understand the effects of human genetics on cholesterol, a team of scientists had 800 people drink a […]

http://www.lslog.com/biogen-to-boost-stake-in-biosims-joint-venture-as-competition-to-its-ms-meds-mounts/Biogen to boost stake in biosims joint venture as competition to its MS meds mounts

Biogen to boost stake in biosims joint venture as competition to its MS meds mounts

Biogen to boost stake in biosims joint venture as competition to its MS meds mounts Biogen is increasing its stake in a biosimilars joint venture shared with Samsung. The companies […]

http://www.lslog.com/exasperated-allergan-investors-recruiting-activists-to-push-for-asset-sales-report/Exasperated Allergan investors recruiting activists to push for asset sales: report

Exasperated Allergan investors recruiting activists to push for asset sales: report

Exasperated Allergan investors recruiting activists to push for asset sales: report Investors aren’t happy with the steps Allergan has taken to remedy its share-price slump—and they’re calling on outsiders to […]